FFF Enterprises Announces 7,000 Counterfeit-Free Days of Biopharmaceutical Distribution

On Sunday, FFF Enterprises will recognize its 7,000^th counterfeit-free day of biopharmaceuticals distribution as the company begins its twentieth anniversary year. FFF’s successful counterfeit-free record translates into more than 120 million grams of intravenous immune globulin and 70 million doses of influenza vaccine administered to patients without the risk of counterfeits inherent in secondary pharmaceutical supply channels.

“Our distribution model has been unique for the 20 years we’ve been in business, and our manufacturing partners, customers – and their patients – are its beneficiaries,” explained Patrick M. Schmidt, president and CEO of FFF. “We purchase only from manufacturers and ship only to healthcare providers. This is the only distribution model that eliminates the risk of counterfeiting, drug diversion and irresponsible pricing so frequently reported in secondary supply channels.”

FFF's distribution method, called Guaranteed Channel Integrity™, has simplified the company’s response to state and federal drug pedigree requirements, which are diverse and sometimes conflicting in their mandates.

“Because of our model, we are recognized as an authorized distributor of record for all our manufacturing partners,” Schmidt said, “which excludes us from some pedigree requirements. But, because our channel is so secure, we implemented our own electronic pedigree in 2004 – well ahead of the industry – to document the security of our channel for our partners and customers.”

FFF looks forward to the next 20 years of counterfeit-free distribution.

FFF Offers Helixate FS in New 2,000 IU Size

We are pleased to offer CSL Behring’s Helixate^® FS in the new 2,000 IU size. Helixate FS is an advanced recombinant FVIII product for the treatment of hemophilia A. For patients who need large doses of Helixate FS, the 2,000 IU vial size reduces reconstitution time by eliminating the need to mix and pool multiple vials.

“Helixate FS, with the new 2000 IU vial, offers patients shorter infusion times, which translates into greater convenience, and will encourage compliance with prescribed treatment," said Robert Lefebvre, CSL's vice president and general manager of U.S. Commercial Operations.

For more information on Helixate FS or any of the products FFF offers, visit www.fffenterprises.com.

From the CDC
Recommended Immunization Schedules for Persons Aged 0—18 Years - United States, 2008

From the CDC
Norovirus Outbreak in an Elementary School—District of Columbia

From the Associated Press
Pharmacists Decry Medicare Drug Payments

From CSL Behring
CSL Behring's Helixate® FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance

From Accountability Central
Medicare Fraud Strike Force Cases Result in Long Prison Terms for Five Healthcare Company Owners

From FDA
FDA Clears First Test Designed to Detect and Identify 12 Respiratory Viruses from Single Sample

From Atlantic Information Services
2008 Outpatient Prospective Payment System Will Reduce ASP Reimbursement for Specialty Rx, Result in Potentially Serious Access Problems, Providers Say

From Reuters
Regular Flu Vaccine May Help Against H5N1 - Study